ACAM2000
Commercial- Indications
- Smallpox
Company intelligence / Profile preview
Acambis developed the FDA-approved ACAM2000® smallpox vaccine, which is stockpiled by the US government for biodefense. Other programs included advanced clinical candidates targeting Japanese encephalitis, West Nile virus, dengue fever, influenza, C. difficile infection, and herpes simplex. The company was acquired by Sanofi Pasteur in 2008 and its lead products were integrated into Sanofi’s portfolio.
3 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Acambis plc.